Return to inventory: Completed Consultations on Foods from Genetically Engineered Plant Varieties
See FDA's memo on BNF No. 000147 for further details
June 19, 2015
Mark Leibman, PhD
800 North Lindbergh Blvd.
St. Louis, MO 63167
Dear Dr. Leibman:
This letter addresses Monsanto Company’s (Monsanto’s) consultation with the Food and Drug Administration (FDA) (Center for Food Safety and Applied Nutrition (CFSAN) and Center for Veterinary Medicine) on genetically engineered corn, MON 87403. According to information Monsanto has provided, MON 87403 corn expresses a variant of the ATHB17 transcription factor protein from Arabidopsis thaliana, lacking the N-terminal 113 amino acids, designated ATHB17Δ113. This protein is intended to increase yield potential by increasing ear biomass at the R1 developmental stage. All materials relevant to this consultation have been placed in a file designated BNF 000147. This file will be maintained in the Office of Food Additive Safety in CFSAN.
As part of bringing this consultation to closure, Monsanto submitted to FDA a summary of its safety and nutritional assessment of the genetically engineered corn, which we received on October 23, 2014. Monsanto submitted additional information, which we received on February 4, 2015. These communications informed us of the steps taken by Monsanto to ensure that this product complies with the legal and regulatory requirements that fall within FDA’s jurisdiction. Based on the safety and nutritional assessment Monsanto has conducted, it is our understanding that Monsanto has concluded that food and feed from MON87403 corn are not materially different in composition, safety, and other relevant parameters from corn-derived food and feed currently on the market, and that genetically engineered MON87403 corn does not raise issues that would require premarket review or approval by FDA.
It is Monsanto’s responsibility to obtain all appropriate clearances, including those from the Environmental Protection Agency and the United States Department of Agriculture, before marketing food or feed derived from MON 87403 corn.
Based on the information Monsanto has presented to FDA, we have no further questions concerning food and feed derived from MON87403 corn at this time. However, as you are aware, it is Monsanto’s continuing responsibility to ensure that foods marketed by the firm are safe, wholesome, and in compliance with all applicable legal and regulatory requirements. A copy of the text of this letter responding to BNF 000147, as well as a copy of the text of FDA’s memorandum summarizing the information in BNF 000147, is available for public review and copying at http://www.fda.gov/bioconinventory.
Dennis M. Keefe, Ph.D.
Office of Food Additive Safety
Center for Food Safety and Applied Nutrition